The therapeutic potential of CRF1 antagonists for anxiety.
about
Stress, dysregulation of drug reward pathways, and the transition to drug dependenceChronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapseBehavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.Role of corticotropin-releasing factor (CRF) receptor-1 on the catecholaminergic response to morphine withdrawal in the nucleus accumbens (NAc)Genoarchitecture of the extended amygdala in zebra finch, and expression of FoxP2 in cell corridors of different genetic profileExtended access cocaine self-administration differentially activates dorsal raphe and amygdala corticotropin-releasing factor systems in ratsPolymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats.Don't stress about CRF: assessing the translational failures of CRF1antagonists.Social defeat stress activates medial amygdala cells that express type 2 corticotropin-releasing factor receptor mRNAInhibition of corticotropin releasing factor expression in the central nucleus of the amygdala attenuates stress-induced behavioral and endocrine responses.Effects of continuously enhanced corticotropin releasing factor expression within the bed nucleus of the stria terminalis on conditioned and unconditioned anxietyRole of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.Progress in corticotropin-releasing factor-1 antagonist development.Effect of pharmacological manipulations of neuropeptide Y and corticotropin-releasing factor neurotransmission on incubation of conditioned fearCRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cuesNeuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight.CRF(1) receptor antagonists attenuate escalated cocaine self-administration in ratsCorticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent ratsA CRF(2) agonist administered into the central nucleus of the amygdala decreases ethanol self-administration in ethanol-dependent rats.Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.Role of corticotropin releasing factor in anxiety disorders: a translational research perspectiveDependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout.Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.SEB-3, a CRF receptor-like GPCR, regulates locomotor activity states, stress responses and ethanol tolerance in Caenorhabditis elegansCorticotropin-releasing factor receptor-1: a therapeutic target for cardiac autonomic disturbances.Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats.Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor.Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin.Corticotropin releasing factor receptor antagonists for major depressive disorder.Stress controversies: post-traumatic stress disorder, hippocampal volume, gastroduodenal ulceration*.From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.Corticotropin releasing factor: a key role in the neurobiology of addictionEffects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.Potential uses of corticotropin-releasing hormone antagonists.Role of Corticotropin-releasing Factor Signaling in Stress-related Alterations of Colonic Motility and Hyperalgesia.Ethanol concentration-dependent effects and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and double type 1 and 2 receptor knockout miceMPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist.CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats.Development of medications for alcohol use disorders: recent advances and ongoing challenges.The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.
P2860
Q24629577-8B80F6AD-3D73-415E-87D7-4C50032A86B7Q24633835-894DEC2E-B77C-4D32-B954-12A8B3964405Q27014879-A50559C9-D27F-45DF-A719-47850C724692Q28484325-8434DFD6-812F-4B6A-A72B-68F9DCCFC439Q28566355-92BD2FF1-FA2D-4A69-B7DB-7925E640EE3FQ28582150-87AFBD9D-FD56-4310-AD76-899E48268F0DQ30389951-B3756466-C259-4950-BE1C-872C732D4177Q30399543-DB7405DB-C363-4F3D-BAF9-825C258BA08EQ30435221-3001B4CD-0202-462B-8E23-3A3C638FD920Q30447564-869AAD56-8C54-454A-82E0-8952999B5717Q30450034-5254CB95-E550-4D8C-84E7-E274BEAFBEEFQ30468942-761EE283-B5E7-4A79-AFF2-C6E72525E0D3Q30475627-CAD0E82A-162D-4D44-AFBE-66D4015A8092Q30477987-9E074FD1-9547-4579-BFEA-28A66633AE65Q30480573-889FA521-D3F2-43BB-9BEF-BC369FA3E80EQ30484216-DAF952A0-743B-469F-8CBB-CABA4C09DC51Q30485809-6E4DB08B-9EB4-4C1B-9A4F-EE1ABEC0830CQ30486793-A43B8D3D-8511-4A48-A667-9501DE71E987Q30486940-A09A85FE-FE21-4494-8FDD-9FFEFCAAA637Q30487401-D400DFB7-665A-4E31-B9B3-CBA36C8F12CDQ30498732-18CE0261-BEB6-4CCF-9AF0-90872C61EDA9Q30499148-F8153F4D-2D62-42DB-A238-E5834F5B666FQ30542062-1F9FA28F-3F31-4D38-A0E4-103D7E77BE63Q30558402-AE0B28DE-6A44-4EAC-93C9-A5C16D2353C9Q33155703-51023F7E-EC6B-4E2D-9688-577C5156DFF1Q33304561-ED7E8ED5-5CB5-47BF-A9F7-2AC0522DD1F2Q33616639-B21DF980-1C3A-4D9E-8575-8863201F5489Q33643476-72C16C99-7440-4055-8A22-1B04D2FBB1AFQ33843656-8CEBBBB0-1AF5-4ED2-81FD-A49FFEFEC636Q34145538-5453BA00-B4B1-4A77-9754-D11F6178D4A3Q34357345-166BFF28-4A13-48A8-863F-AA047BCFC40EQ34421204-CF391C09-8068-487A-8661-C9E928D80BCCQ34517084-3971B291-3B1C-4B34-A4C1-4E0A423B09E0Q34587976-722CF091-5A19-43A1-8025-D4EF9C7B300DQ34882307-103E5E11-FCE0-4BA7-A6A9-7ADCAA25EF54Q35852967-EC281CE0-BD28-4CC9-8149-42566510B88FQ35869282-30690D94-236A-44BD-9E6F-64F679D4E021Q36089365-6B238B90-DDE5-4BDD-99EE-1FAEBAAF243DQ36150622-209C51EE-0A10-43F1-88A1-E82AA217FC41Q36219686-E22F2A29-F23B-431E-A8F7-220CC0AD7A6E
P2860
The therapeutic potential of CRF1 antagonists for anxiety.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The therapeutic potential of CRF1 antagonists for anxiety.
@ast
The therapeutic potential of CRF1 antagonists for anxiety.
@en
type
label
The therapeutic potential of CRF1 antagonists for anxiety.
@ast
The therapeutic potential of CRF1 antagonists for anxiety.
@en
prefLabel
The therapeutic potential of CRF1 antagonists for anxiety.
@ast
The therapeutic potential of CRF1 antagonists for anxiety.
@en
P2860
P1476
The therapeutic potential of CRF1 antagonists for anxiety.
@en
P2093
Eric P Zorrilla
George F Koob
P2860
P304
P356
10.1517/13543784.13.7.799
P407
P577
2004-07-01T00:00:00Z